Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bial
Biotech
Bial bails after Parkinson’s fail, axing asset over phase 2 miss
Bial has stopped development in a subpopulation of Parkinson’s disease patients after its phase 2b trial missed its primary endpoint.
Nick Paul Taylor
Jun 9, 2026 5:22am
EuroBiotech:​​​ ​​​More​​​ ​​​Articles​​​ ​​​of​​​ ​​​Note
Feb 16, 2017 9:22am
EMA updates first-in-human trial guidance
Nov 16, 2016 12:10pm
French prosecutors to investigate manslaughter charge over fatal trial
Jun 14, 2016 6:36am
EMA to hold major review after fatal French trial
May 24, 2016 6:35am
EuroBiotech: More Articles of Note
Apr 21, 2016 9:06am
